Chimeric antigen receptor NK (CAR-NK) cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a specific tumor antigen and then integrates the fragment into the transmembrane chain segment composed of different combinations of molecules such as CD3-ζ, CD137, NKG2D and DAP10, forming a forming a recombinant plasmid CAR. The CAR will be transduced into the NK cells (from patients or healthy donors) and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-NK cells will be generated to attack and eventually ablate the tumor.
Schematic diagram of CAR-NK technology
Advantages of CAR-NK cell therapy
More efficient killing: Compared with T cells as the carrier, NK cells are natural killers of tumor cells with higher efficiency.
Capable of allogeneic treatment: Unlike T cells, NK cells will not kill the normal cells in the host, making it possible to realize allogeneic treatment.
Less toxic reaction and side effects: Unlike CAR-T cells, CAR-NK cells survive shortly in vivo after tumor elimination, so long-term cytotoxicity is negligible. This advantage is particularly important for the treatment of solid tumors with tumor-associated antigens as targets.